Lineage Cell Therapeutics, Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Lineage Cell Therapeutics, Inc. (LCTX) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $3.10 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-05
- Lineage Cell Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2019-09-30 was $1.00M.
- Lineage Cell Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2019-06-30 was $1.20M.
- Lineage Cell Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $3.10M, a 46.55% decline from fiscal 2024.
- Lineage Cell Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $5.80M.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 3 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 6 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 9 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|---|---|---|
| 2025-12-31 | $3.10M 10-K · filed 2026-03-05 | |||
| 2024-12-31 | $5.80M 10-K · filed 2026-03-05 | |||
| 2019-09-30 | $1.00M 10-Q · filed 2019-11-12 | $2.20M derived: sum of 2 quarters · filed 2019-11-12 | $6.60M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $1.20M 10-Q · filed 2019-08-08 | $5.60M 10-Q · filed 2019-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |